0001209191-15-037578.txt : 20150430 0001209191-15-037578.hdr.sgml : 20150430 20150430185158 ACCESSION NUMBER: 0001209191-15-037578 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150428 FILED AS OF DATE: 20150430 DATE AS OF CHANGE: 20150430 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avalanche Biotechnologies, Inc. CENTRAL INDEX KEY: 0001501756 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 205258327 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1035 O?BRIEN DRIVE, SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-272-6269 MAIL ADDRESS: STREET 1: 1035 O?BRIEN DRIVE, SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gasmi Mehdi CENTRAL INDEX KEY: 0001614875 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36579 FILM NUMBER: 15821281 MAIL ADDRESS: STREET 1: C/O AVALANCHE BIOTECHNOLOGIES, INC. STREET 2: 1035 O'BRIEN DRIVE, SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-04-28 0 0001501756 Avalanche Biotechnologies, Inc. AAVL 0001614875 Gasmi Mehdi C/O AVALANCHE BIOTECHNOLOGIES, INC. 1035 O'BRIEN DRIVE, SUITE A MENLO PARK CA 94025 0 1 0 0 VP, Pharmaceutical Development Common Stock 2015-04-28 4 M 0 1000 2.75 A 8000 D Common Stock 2015-04-28 4 S 0 1000 35.667 D 7000 D Stock Option (Right to Buy) 2.75 2015-04-28 4 M 0 1000 0.00 D 2024-03-04 Common Stock 1000 98000 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. This transaction was executed in multiple trades in prices ranging from $35.08 to $35.86, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Twenty-five percent (25%) of the shares subject to the option vested and became exercisable on the first anniversary measured from March 5, 2014, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. /s/ Michael Swartzburg, Attorney-in-Fact for Mehdi Gasmi 2015-04-30